Pioglitazone

Generic Name: Pioglitazone

Brand Names: Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₀N_₂O_₃S

CAS Number: 111025-46-8

Unique Ingredient Identifier: X4OV71U42S

Background: Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...

Indication: Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.

Associated Conditions: Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)

Phase 2

Terminated

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-09-30

Last Posted Date: 2011-08-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 100

Registration Number: NCT00229684

Locations: 🇺🇸
Research Site, Seattle, Washington, United States

GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus

Phase 3

Terminated

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-09-27

Last Posted Date: 2010-11-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 1100

Registration Number: NCT00226330

Locations: 🇬🇧
Research Site, Wiltshire, United Kingdom

Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)

Phase 4

Completed

Conditions: Nonalcoholic Steatohepatitis

Interventions: Drug: Placebo
Drug: Pioglitazone

First Posted Date: 2005-09-27

Last Posted Date: 2009-10-14

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 55

Registration Number: NCT00227110

Locations: 🇺🇸
Audie L Murphy VA Hospital, San Antonio, Texas, United States

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Glimepiride
Drug: Pioglitazone

First Posted Date: 2005-09-23

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 547

Registration Number: NCT00225277

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Pioglitazone
Drug: Glimepiride

First Posted Date: 2005-09-23

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 458

Registration Number: NCT00225264

Actos Now for Prevention of Diabetes (ACT NOW)

Phase 3

Completed

Conditions: Type 2 Diabetes
Impaired Glucose Tolerance

Interventions: Drug: Placebo
Drug: Pioglitazone

First Posted Date: 2005-09-22

Last Posted Date: 2016-08-11

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 602

Registration Number: NCT00220961

Locations: 🇺🇸
SUNY Health Science Center, Brooklyn, New York, United States
🇺🇸
Carl T. Hayden VA Medical Center, Phoenix, Arizona, United States
🇺🇸
University of Tennessee, Memphis, Tennessee, United States

and more 5 locations

Pioglitazone Protects Diabetes Mellitus (DM) Patients Against Re-Infarction (PPAR Study)

Phase 4

Terminated

Conditions: Diabetes Mellitus
Myocardial Infarction

Interventions: Other: control
Drug: pioglitazone

First Posted Date: 2005-09-21

Last Posted Date: 2018-05-23

Lead Sponsor: National Cerebral and Cardiovascular Center, Japan

Target Recruit Count: 630

Registration Number: NCT00212004

Locations: 🇯🇵
National Cardiovascular Center, Suita, Osaka, Japan

Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

Phase 4

Completed

Conditions: Insulin Resistance
Type 2 Diabetes Mellitus

First Posted Date: 2005-09-21

Last Posted Date: 2010-02-15

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 140

Registration Number: NCT00212290

Locations: 🇺🇸
VA Puget Sound Health Care System (American Lake Campus), Tacoma, Washington, United States
🇺🇸
VA Puget Sound Health Care System (Seattle Campus), Seattle, Washington, United States

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

Phase 4

Terminated

Conditions: Polycystic Ovary Syndrome
Obstructive Sleep Apnea

Interventions: Drug: depot leuprolide plus estrogen/progestin replacement
Device: continuous positive airway pressure (CPAP)
Procedure: REM frag
Drug: pioglitazone
Procedure: SWS supp

First Posted Date: 2005-09-20

Last Posted Date: 2023-03-21

Lead Sponsor: University of Chicago

Target Recruit Count: 37

Registration Number: NCT00203996

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Study In People With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-09-20

Last Posted Date: 2017-03-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 448

Registration Number: NCT00196989

Locations: 🇷🇺
GSK Investigational Site, Yaroslavl, Russian Federation

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy